<DOC>
	<DOCNO>NCT02480010</DOCNO>
	<brief_summary>This study evaluate efficacy safety intravenous ( IV ) pertuzumab participant hormone-refractory prostate cancer previous chemotherapy . Participants enrol two stage , first ( Cohort A ) low 420-mg dose second ( Cohort B ) high 1050-mg dose base upon observation Cohort A . Up 50 participant may enter either cohort , total enrollment 46 73 participant across 9 study center .</brief_summary>
	<brief_title>A Study Pertuzumab Participants With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<criteria>Adults great ( &gt; ) 18 year age Histologically document adenocarcinoma prostate resistant hormone therapy , progress 4 6 week follow antiandrogen withdrawal Prostatespecific antigen ( PSA ) value least 20 ng/mL among asymptomatic mildly symptomatic disease Karnofsky performance status ( KPS ) least 80 percent ( % ) Castrate testosterone le ( &lt; ) 50 ng/dL Life expectancy least 12 week Left ventricular ejection fraction ( LVEF ) least 50 % Adequate hematologic , hepatic , renal function Prior chemotherapy , radionucleotide therapy , immunotherapy prostate cancer Systemic corticosteroid within 1 month prior Screening Bisphosphonates within 6 month , narcotic analgesic within 2 week , investigational agent 28 day study drug Prior cumulative doxorubicin dose &gt; 360 mg/m^2 equivalent Central nervous system ( CNS ) pulmonary metastases Other malignancy , except adequately treat basal squamous cell skin cancer Significant cardiovascular disease Active/uncontrolled concurrent illness infection Major surgery traumatic injury within 4 week study drug</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>